GlassScriptPhysician profile
Joseph Ripperger
NPI 1578510244
$6,388.80
in general payments reported to CMS, 2019-2025
29 companies · $1,090 in 2025
The $1,090 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,007 · 2020: $461 · 2021: $350 · 2022: $659 · 2023: $1,453 · 2024: $1,369 · 2025: $1,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,812 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,811.63 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $933.22 | 2019-2025 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $930.01 | 2019-2025 | Austedo Xr, Austedo, Uzedy |
| Abbvie INC. | $917.11 | 2021-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $643.67 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $600.71 | 2020-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $367.37 | 2019-2025 | Trintellix |
| Corium, LLC | $365.11 | 2022-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $350.82 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $224.86 | 2019-2025 | Lybalvi, Aristada |
| Ironshore Pharmaceuticals INC. | $118.96 | 2019-2023 | Jornay Pm |
| Shire North American Group INC | $109.28 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $87.76 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $85.52 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $84.71 | 2021-2022 | |
| Allergan, INC. | $76.88 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $66.86 | 2020-2021 | |
| Tris Pharma INC | $63.52 | 2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $61.88 | 2024-2025 | Qelbree |
| Neos Therapeutics, LP | $50.63 | 2019-2024 | Adzenys Xr-Odt |
| Lundbeck LLC | $50.20 | 2019-2023 | Abilify Asimtufii, Rexulti |
| Adlon Therapeutics L.P. | $44.02 | 2020 | |
| Avanir Pharmaceuticals, INC. | $27.12 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $23.27 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $22.21 | 2025 | Quviviq |
| Vanda Pharmaceuticals INC. | $21.42 | 2019 | |
| Indivior INC. | $18.84 | 2019 | |
| Neuronetics, INC. | $17.03 | 2019 | |
| Mdd US Operations, LLC | $13.80 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Ripperger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.